

Introduction to PHC Group

PHC Holdings Corporation



PHC
GROUP

Contents

1 PHC Group Overview P.03

2 Our History P.06

3 Mission / Vision / Values P.08

4 Business Domains P.12

Diabetes Management P.13



Healthcare Solutions P.19



mediford P.21




Diagnostics & Life Sciences P.24



PHC P.26

5 Sustainability P.32

1 PHC Group Overview



| | |
|--|--|
| Company Name | PHC Holdings Corporation |
| Business Address/ Head Office | 15F DAI-ICHI LIFE HIBIYA FIRST 1-13-2 Yurakucho, Chiyoda-ku, Tokyo 100-8403, Japan |
| Founded | 1969 (Founded as Matsushita Kotobuki Electronics Co., Ltd.) |
| Representative | President, Representative Director and CEO Kyoko Deguchi |
| Capital | 48,623 million yen* |
| Listed Market | Tokyo Stock Exchange Prime Market (TSE 6523) |
| Main Business | <ul style="list-style-type: none">• Diabetes Management• Healthcare Solutions• Diagnostics & Life Sciences |

*As of March 31, 2025

PHC Group is a global network of healthcare companies dedicated to improving health through digital and precision technology. Since our founding in Japan in 1969, we have been driving better health through solutions in diagnostics, life sciences, diabetes management, and healthcare IT.

PHC Group Strengths

Industry-Leading Products and Services

Manufacturing Excellence with High Precision and Quality

Global Reach to a Diverse Range of Healthcare Practitioners

Revenue^{*1}

361.6^{bn yen}

Operating businesses globally

PHC Group's Revenue Geographic Mix

| Region | Percentage |
|---------------|------------|
| Japan | 43% |
| Europe | 23% |
| North America | 22% |
| Other | 12% |

Employees^{*2}

9,041

Diversified Talent

| Category | Percentage |
|---------------|------------|
| Japan | 61% |
| Outside Japan | 39% |

Subsidiaries^{*2}

86

Growing a Global Network


Countries Where Our Products are Available^{*3}

>125

Extensive Global Sales Performance

*1 FY2024, FX rate: 1 US\$ = 152JPY, 1 euro€=164JPY *2 As of March 2025 *3 As of March 2026

2 Our History



*1 Listed on October 14, 2021 (TSE 6523) *2 Merged the Medicom Division of PHC Corporation and PHC Medicom Corporation. *3 Integrated the clinical trial business of LSI Medience Corporation to its subsidiary, and changed the company to a wholly-owned subsidiary of PHC Holdings Corporation.

3

Mission / Vision / Values

MISSION

We contribute to the health of society through our diligent efforts to create healthcare solutions that have a positive impact and improve the lives of people.

VISION

Be a leader in precision technology that powers the future of healthcare.

VALUES

Curiosity
Courage to Act
Respect & Collaboration
Integrity



Diabetes Management

Diabetes Management Business Unit



- Blood Glucose Monitoring Systems
- Digital Diabetes Management Solutions

Healthcare Solutions

Clinical Testing Business Unit

Healthcare IT Solutions Business Unit

CRO Business Unit



- Clinical Testing
- Food Sanitation & Hygiene Analysis
- Doping control sample analysis

- IT Systems for Clinics, Hospitals, Pharmacies, and Dental Clinics
- Operational Efficiency Solutions for Corporations, Health Insurance Associations, and Health Checkup Institutions

- Non-clinical Contract Research
- Bioanalysis Services
- Central Laboratory Services

Diagnostics & Life Sciences

Pathology Business Unit


Life Sciences Business Unit



- Anatomical Pathology Instruments, Consumables, and Microscope Slides
- Digital Pathology and Software Solutions
- Instrument Maintenance Service

- Life Science Research/Medical Support Equipment
- Diagnostic Reagents and Instruments
- Instrument Maintenance Service
- Development and Manufacturing Contract Service

Our global business includes **86^{*1}** subsidiaries, with sales in more than **125^{*2}** countries and regions.



*1 * Numbers as of March 2025. *2 Numbers as of March 2026.

4 Business Domains

Ascensia Diabetes Care is a global leader in diabetes technology. We have been entirely dedicated to improving the health and lives of people with diabetes for over 80 years.

Our Strengths

- 1 **Serving people with diabetes in more than 100 countries and regions**
- 2 **Global sales network to meet diverse needs of diabetes management**
- 3 **Highly innovative product portfolio based on accuracy and patient needs**
- 4 **Integrated monitoring devices and digital technologies to support more effective self-management**

Target Customers



Our blood glucose monitoring systems are highly accurate, easy-to-use, and widely accepted by people with diabetes around the world. Ascensia offers solutions to effectively manage diabetes while leveraging monitored data through the integration of digital technology.


Blood Glucose Monitoring (BGM) Systems

Easy-to-use, highly accurate blood glucose monitoring for daily use by people with diabetes



Digital Diabetes Management Solutions

Consolidated diabetes management solutions that support more effective self-management and data sharing for PWDs



History of Innovation

First Test for Measuring Glucose in Urine (1941)



First Portable Blood Glucose Meter (1969)



PHC Corporation serves as an Original Equipment Manufacturer (OEM), supplying strategic partners in Japan with technology to contribute to the detection, monitoring, and treatment of diabetes.

Blood Glucose Monitoring System (BGM)

Supplied to Arkray, Inc.



Blood Glucose Monitoring System for Hospitals/Clinics

Supplied to SANWA KAGAKU KENKYUSHO CO., LTD.



Lancing Devices/ Lancets

Supplied to SANWA KAGAKU KENKYUSHO CO., LTD.



History of Innovation

Auto sample fill blood glucose sensing system for blood glucose monitoring system (1991)



Manufacturing sites in Indonesia and Japan, and operations in more than 30 countries and regions.



● ...Headquarters of Group Companies ● ...Sales Sites ○ ...R&D
(As of March 2026)

Since the founding of its predecessor, Medical Science Corporation, in 1975, the business that is now LSI Medience has contributed to the prevention, early detection, and treatment of diseases through clinical testing.

Our Strengths

- 1 **Diverse testing portfolio with more than 4,000 types of tests**
- 2 **High-quality testing with international certification***
- 3 **Large sales network extending across Japan**

Target Customers

Hospitals/Clinics



Food Manufacturers



Some products and services may not be available in all countries

* Certified according to the international standard ISO 15189 for operating clinical laboratories and by the College of American Pathologists (CAP).

LSI Medience provides services in clinical testing through laboratory analysis, including cancer diagnostics, genetic testing, and sports doping testing.

Clinical Testing

Its Laboratory Automation System responds to advanced clinical testing needs and offers a wide variety of tests, including biochemistry, hematology, immunology, microbiology, and genetics.



Doping Tests

Support global anti-doping activities as Japan's only laboratory certified by the World Anti-Doping Agency (WADA)*. Implements sample analysis with the latest equipment and advanced analytical methodologies.



* World Anti-Doping Agency

Some products and services may not be available in all countries

Wemex is a healthcare solution provider that contributes to the digital transformation of healthcare. The business has a long history of providing cutting-edge healthcare IT for clinics and pharmacies in Japan, starting with launching Japan's first receipt computer in 1972.

Our Strengths

- 1 Extensive medical IT knowledge and experience accumulated over half a century**
- 2 Strong customer base in the market segments of clinics and pharmacies**
- 3 Accurate and prompt support services through our nationwide business locations in Japan**
- 4 Comprehensive ICT-based solutions that enable online collaboration between medical institutions and patients**

Target Customers



Some products and services may not be available in all countries

Wemex advances digital transformation in healthcare in Japan by pioneering innovation-driven solutions and promoting the Japanese government's medical policies. Through initiatives such as streamlining operations in clinics, hospitals, pharmacies, and dental clinics, as well as preventive care, we aim to reduce workloads for healthcare providers, support regional healthcare, and contribute to improving the quality of medical services.

**Medical-Receipt Computers
Clinic & Hospital Market Share**



**Electronic Medical Record Systems
Clinic Market Share**



*1 Source: Fuji Keizai Co., Ltd. "2022 Current Status and Future Outlook of the Medical Collaboration and Medical Platform-Related Market" based on company share (volume basis) for medical-receipt computers (PHC Actual) in 2020.

*2 Source: Fuji Keizai Co., Ltd. "2025 Current Status and Future Outlook of the Medical and Healthcare DX-Related Market" based on company share (value basis) for on-remises/cloud-based electronic medical record systems for clinics in 2024.

Clinics

Offering cloud-based, on-premise, and hybrid electronic medical record (EMR) systems to suit operational policies and specific needs. With over 50 years of expertise in medical-receipt computer development and comprehensive support services, these systems quickly adapt to digital transformation requirements such as Online Eligibility Verification and electronic prescriptions, while achieving operational efficiency and reducing workloads for healthcare providers.

Cloud-Based Electronic Medical Record System

Medicom クラウドカルテ

Hybrid Electronic Medical Record System

medicom-HRf Hybrid Cloud

Hospitals

Offering a range of electronic medical record solutions tailored to specific operational scales and needs, we support seamless digital transformation in healthcare. Our systems enhance operational efficiency and contribute to improving the quality and accessibility of regional healthcare in Japan through real-time telemedicine systems that help compensate for shortages in medical resources.

Cloud-Based Electronic Medical Record System for Small to Medium-Sized Hospitals

Open-Karte Cloud

In-House Receipt Checking System

べてらん君 collaboration Plus+

Pharmacies

We support pharmacists' operational efficiency primarily through medical-receipt computers and electronic medication history systems. Our total solutions, tailored to a pharmacy's business growth, include point-of-sale data analytics and head office management systems.

Hybrid Electronic Medication History System

PharnesX Hybrid Cloud

Hybrid Electronic Medication History System for Regional Primary Pharmacies

Pharma-SEED EX

Wellness (Prevention/Pre-Symptomatic Care)

With a focus on preventive healthcare, our solutions uniquely deliver efficiency-enhancing tools tailored for companies and health insurance associations, streamlining processes and helping to improve health outcomes. These support multifaceted healthcare approaches, including outsourced administration services for health checkups, stress checks, and Specific Health Guidance*3.

Specific Health Guidance (SHG) Support System

Wemex 保健指導システム

Outsourcing Clerical Services for Health Checkups

Wemex 健診代行

*3 Specific Health Guidance is Japan's nationwide lifestyle improvement program targeting adults with metabolic syndrome.

Mediford was established in 2023, integrating the clinical trial business previously under LSI Medience Corporation and the non-clinical testing business formerly under LSIM Safety Science Institute Corporation.

Our Strengths

- 1 **Broad range of services** from non-clinical testing to clinical research (clinical trials)
- 2 **Reliable services** provided by GLP*-compliant contract research organizations
- 3 **Advanced analysis technologies** tailored to new modalities (nucleic acid medicines, antibody drugs, gene therapies, and regenerative medicine products)
- 4 **Consulting from non-clinical trial strategy development to implementation**

Target Customers

Pharmaceutical Companies/
Drug Discovery Ventures

Business Enterprises (chemicals,
agrochemicals, foods, cosmetics, etc.)



Universities

Public
Institutions



Some products and services may not be available in all countries

*GLP: Good Laboratory Practice, a standard to ensure the safety and reliability of pharmaceuticals.

Mediford offers services that support a wide range of research and development, from the exploratory phase of drug development to clinical testing, using reliable testing and analytical capabilities accumulated through extensive experience in contract research.

Non-clinical Testing Services

Offers a wide range of services, from studies for regulatory approval applications to exploratory studies in the early stages of research and development, as well as consulting services using GLP-compliant facilities and cutting-edge equipment.



Bioanalysis Services

Develops analytical methods for drugs, metabolites, and biomarkers of biological samples, conducts validation of analytical methods, and measures actual samples.




Central Laboratory Services

Supports a series of processes from specimen collection to batch testing for clinical research (clinical trials and clinical testing) conducted at medical institutions in Japan, and responds to demands for global drug development.



R&D, manufacturing, laboratory, and sales sites across Japan



■ ...R&D or Manufacturing Sites

(As of March 2026)

| | LSI Medience | WEMEX | mediford |
|--|--|--|---|
| | | | |
| | Headquarters (Itabashi-ku, Tokyo) | Headquarters (Shibuya-ku, Tokyo) | Headquarters (Itabashi-ku, Tokyo) |
| R&D or Manufacturing Sites | <ul style="list-style-type: none"> • Itabashi/Tokyo | <ul style="list-style-type: none"> • Tokyo • Saitama • Nagano • Mie • Fukuoka | <ul style="list-style-type: none"> • Itabashi/Tokyo • Ibaraki • Kumamoto |
| Sales Sites | approx. 60 | 45 | 7 |
| Laboratories (Registered sanitary inspection offices) | 32 | - | 3 |

EpreDia is a global leader in anatomical pathology, working to improve patient outcomes by providing a comprehensive range of solutions supporting precision cancer diagnostics and research. Every second of every day, 48 EpreDia products are used in the battle against cancer.

Our Strengths

1

High-quality, comprehensive product lineup that improves the efficiency and accuracy of pathology processes

2

Trusted customer relationships and high market shares built since 1937

3

Strong sales network established mainly in Europe, the U.S., and Asia, including Japan

Target Customers

Hospitals/Clinics



Research Institutions/Universities



Pharmaceutical Companies



From instruments to microscope slides and staining reagents, Epredia's diagnostic solutions help to improve workflow efficiency from specimen collection to analysis. Together they enable safer, quicker, and more accurate diagnoses of cancer.

Histology Consumables

Bringing much needed standardization to non-standardized patient testing environments

Microscope Slides



Histology Staining Solutions



Laser Slide Printers and Laser Cassette Printers

Enhancing laboratory efficiency and sample traceability



Tissue Processors

The foundation for diagnostic confidence



Microtomes and Cryostats

Supporting a comfortable sectioning workflow



Digital Pathology

Enabling laboratories today while preparing for the future



In our Life Sciences business, we provide value to life sciences research and medical practice through advanced technological expertise and manufacturing excellence with high precision. Our diverse product lineup includes indispensable research and medical support equipment for long-term biological sample storage and cell culture, cutting-edge solutions for cell and gene therapy (CGT), as well as diagnostic instruments and testing/analysis systems. In addition, we proudly operate a robust sales and service network across 110 countries and regions.

Our Strengths

- 1 Industry-leading, **high-performance, and high-quality products and services** trusted by leading pharmaceutical companies and public certification organizations
- 2 An extensive product portfolio designed to meet diverse needs, from life science research to medical practice
- 3 **Proprietary technologies and manufacturing excellence** with high precision to achieve uncompromising usability while responding to diverse customer needs
- 4 **Strong market shares** across the globe and a **solid and extensive customer base**

Target Customers



Through three segments of solutions in life science, pharmacy, and food catering, we create new values in life science research and medical practice.

| | | | |
|--|--|---|---|
| <h3>Ultra-Low Temperature Freezers</h3> <p>Contributes to reducing global environmental impact with industry-leading^{*1} energy-saving performance; high usability supports research activities</p>  <p>in Japan Globally</p> <p>1^{*2} 2^{*2}</p> | <h3>CO₂ Incubators</h3> <p>Superior control technology and unique anti-contamination features help to ensure an optimal cell culture environment and improve efficiency and reproducibility</p>  <p>in Japan Globally</p> <p>1^{*2} 2^{*2}</p> | <h3>Pharmaceutical Refrigerators with Freezer / Pharmaceutical Refrigerators</h3> <p>Contributes to reducing greenhouse gas emissions through its remarkable energy-saving performance, while preventing quality degradation of pharmaceutical products with its precise temperature control technology</p>  <p>in Japan Globally</p> <p>1^{*2} 4^{*2}</p> | <h3>IoT Lab Management Solution</h3> <p>Real-time cloud integration of equipment operation data. Contributes to improved quality control and enhanced facility management operations.</p>   |
| <h3>Live Cell Metabolic Analyzer</h3> <p>Without sampling, it measures cellular metabolic changes in real time and continuously with proprietary high-precision in-line sensors. Supports research in areas such as cancer and stem cells.</p>  <p>LiCellMo™</p> | <h3>Cell Expansion Bioreactor System^{*3}</h3> <p>Automatically replaces culture medium based on in-line sensor readings that visualize metabolic changes. Continuously optimizes the cell culture environment to contribute to improving the Quality, Cost, and Delivery (QCD) of manufacturing processes.</p>  <p>LiCellGrow™</p> | <h3>Automatic Tablet Counting and Packaging Systems</h3> <p>Reduces medication errors and the workload of pharmacists</p>  | <h3>Food Catering Carts</h3> <p>Assists with the optimal temperature of meals for hospitalized patients, reducing workload and improving efficiency of food delivery</p>  |

*1 ENERGY STAR certification *2 In-house study *3 Currently under development outside of Japan as of March 2026.

PHC Corporation contributes to real-time testing in medical practices through its highly accurate diagnostic reagents, developed from the industry's first latex technology, and its compact POCT (point of care testing) devices.

Diagnostic Reagents

Offers a wide range of in vitro diagnostic reagents that measure blood components, including blood coagulation and fibrinolysis. Contributes to rapid testing with immunochromatography reagents that detect influenza and COVID-19 viruses.



Diagnostic Instruments

Immunoassay analyzer for cardiac disease, sepsis, and gonad-related markers ensures highly sensitive and rapid measurement. Responds to needs ranging from emergency wards to large-scale central laboratories with instruments such as fully automated blood coagulation testers.



Compact immunoanalyzer with superior assay performance

Fully automated blood coagulation testers

History of Innovation

Measuring equipment using latex aggregation Immunoassay method (LPIA-1) globally (1982)



We collaborate with partners to contribute to the detection and treatment of disease.

Motorized Digital Injector

Supplied to JCR Pharmaceuticals Co., Ltd.



Motorized Digital Injector

Supplied to Pfizer Inc.




Motorized Digital Injector

Supplied to Teijin Pharma Limited



POC System (For HbA1c/lipid/CRP testing)

Supplied to Roche Diagnostics International Ltd.




Fractional-exhaled Nitric Oxide (FeNO) Measuring Device*

Supplied to NIOX Group PLC



*The U.S. FDA approved

Manufacturing facilities in Europe, the U.S., and Asia. Sales offices in 14 countries for EpreDia and eight countries for PHC.



EpreDia Holdings Ltd. Headquarters (U.S.)

● ...Headquarters of Group Companies ● ...Manufacturing Sites ○ ...Sales Sites ○ ...R&D



Manufacturing Sites

- EpreDia Holdings Ltd. (U.S., UK, China)
- Fa-Tech Diagnostics Italia S.R.L. (Italy)
- Laurypath (France)
- Microm Microtech France (France)

Sales Sites 14 countries



Manufacturing Sites

- PHC Corporation (Japan)
- PT PHC Indonesia (Indonesia)

Sales Sites 8 countries

- PHC Corporation (Japan)
- PHC Corporation of North America (U.S.)
- PHC Corporation (Shanghai) Ltd. (China)
- PHC Europe B.V. (Netherlands/UK/France/UAE※)
- SciMed (Asia) Pte Ltd (Singapore)
- PT PHC Sales Indonesia (Indonesia)

※ Marketing Site

(As of March 2026)



(As of March 2026)



Sales Sites

- Tokyo
- Osaka
- Fukuoka



Sales Sites

- Hokkaido
- Miyagi
- Tokyo (Headquarters)
- Kanagawa
- Aichi
- Osaka
- Hiroshima
- Fukuoka

Manufacturing Sites

- Chiba (Narita Plant)
- Gunma (Oizumi Plant)
- Ehime (Matsuyama Plant)
- Tokushima (Wakimachi Plant)

5 Sustainability

Environment



We aim to become carbon neutral by 2040. This will be achieved through our materiality topics.

- Climate Change
- Preservation of Natural Resources
- Circularity

www.phchd.com/global/sustainability/environment

Social



By providing high-quality, cutting-edge products, we contribute to the development of new treatments and the quality of medical care.

- Healthcare innovation
- Product excellence
- Supply chain
- Expanded access
- People & culture

www.phchd.com/global/sustainability/social

Governance



We will ensure the trust of our stakeholders through compliance with laws, ethical conduct, early detection of risks, and appropriate responses.

- Corporate Governance
- Risk management
- Cybersecurity

www.phchd.com/global/sustainability/governance

Participation in sustainability initiatives

Near-term Science Based Targets Validated By Global Organization Science Based Targets initiative*1



*1 A corporate climate action organization that checks and validates the scientific basis of CO₂ emissions reduction targets set by companies worldwide. It acknowledges that approaches to reducing emissions are scientifically grounded and consistent with the Paris Agreement's goal of limiting global temperature rise to below 1.5°C relative to pre-industrial levels. <https://sciencebasedtargets.org/>

Disclosed our environmental information through CDP*2



*2 A non-governmental organization (NGO) managed by a UK-based charity that runs the global disclosure system for investors, companies, cities, states, and regions to manage their environmental impacts since its inception in the year 2000. www.cdp.net/en

Rating

Earned the Bronze Medal in EcoVadis' Sustainability Assessment*3



*3 Environment, Labor & Human Rights, Ethics, and Sustainable Procurement, based on thousands of external sources, such as NGOs, labor unions, international organizations, local governments, and audit institutions. EcoVadis is an independent collaborative platform that has evaluated more than 130,000 companies and organizations in 180 countries. ecovadis.com/

Selected as a constituent of the MSCI Japan Equity ESG Select Leaders Index*4 Ranked AA in the latest MSCI ESG Ratings

2024 CONSTITUENT MSCI NIHONKABU ESG SELECT LEADERS INDEX



*4 This index is comprised of companies that excel in ESG evaluation among the constituents of the parent index (MSCI Nihonkabu Equity IMI Index); 517 companies have been selected as of January 2024. www.msci.com/our-solutions/indexes/nihonkabu-esg-select-leaders-index

